Actively Recruiting
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Led by University of Oxford · Updated on 2026-04-14
3000
Participants Needed
4
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other. AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator
CONDITIONS
Official Title
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient understands the procedures and agrees to participate with informed consent
- Adults aged 18 to 60 years at time of consent
- Early symptomatic influenza (A or B) with at least one symptom (fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea, sore throat) within 4 days
- Positive influenza test by rapid antigen or RT-PCR within last 24 hours with Ct value <30
- Able to walk unaided and perform daily activities
- Willing and able to follow study procedures and attend follow-up visits
You will not qualify if you...
- Taking medications that could interact with study drugs or have antiviral activity
- Chronic illness requiring long-term treatment or significant comorbidities
- Body mass index of 35 kg/m2 or higher
- Abnormal lab results at screening including hemoglobin <10 g/dL, platelet count <100,000/uL, ALT >2 times upper limit, total bilirubin >1.5 times upper limit, or eGFR <70 ml/min/1.73m2
- Female participants who are pregnant, breastfeeding, or actively trying to conceive (women on oral contraceptives are eligible)
- Allergy or contraindication to any study drugs
- Participation in another interventional influenza or COVID-19 therapeutic trial
- Clinical signs of pneumonia such as shortness of breath, low oxygen levels, or lung crackles
- Known current co-infection with SARS-CoV-2
- Received live attenuated influenza vaccine within 3 weeks prior to study entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Universidade Federal de Minas Gerais
Minas Gerais, Brazil
Actively Recruiting
2
Laos-Oxford-Mahosot Wellcome Trust Research unit
Vientiane, Laos
Actively Recruiting
3
Sukraraj Tropical & Infectious Disease Hospital
Kathmandu, Nepal
Actively Recruiting
4
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand, 10400
Actively Recruiting
Research Team
W
William Schilling, MD
CONTACT
N
Nicholas J White, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
11
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here